Tumor suppressor activity of CCAAT/enhancer binding protein a is epigenetically down-regulated in head and neck squamous cell carcinoma

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4657-4664

  Bennett, Kristi L ^a   Hackanson, Björn ^b,d   Smith, Laura T ^b   Morrison, Carl D ^c   Lang, James C ^b   Schuller, David E ^b   Weber, Frank ^e   Eng, Charis ^e   Plass, Christoph ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

^e TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; TRANSCRIPTION FACTOR;

ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RNA ISOLATION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

AZACITIDINE; CARCINOMA, SQUAMOUS CELL; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM METASTASIS; TRANSFECTION;

EID: 34250332520     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4793     Document Type: Article

References (45)

1. St John MA, Abemayor E, Wong DT. Recent new approaches to the treatment of head and neck cancer. Anticancer Drugs 2006;17:365-75.
2. Li XM, Di B, Shang YD, et al. [Analysis of risk factors in the prediction of distant metastases of head and neck squamous cell carcinomas]. Zhonghua Er Bi Yan Hou Ke Za Zhi 2004;39:171-5.
3. van Oijen MG, Slootweg PJ. Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits? Cancer Epidemiol Biomarkers Prev 2000;9:249-56.
4. Gupta T, Agarwal JP. Planned neck dissection following chemo-radiotherapy in advanced HNSCC. Int Semin Surg Oncol 2004;1:1-6.
5. Smiraglia DJ, Smith LT, Lang JC, et al. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 2003;40:25-33.
6. Marsit CJ, McClean MD, Furniss CS, et al. Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Cancer 2006;119:1553-7.
7. Estecio MR, Youssef EM, Rahal P, et al. LHX6 is a sensitive methylation marker in head and neck carcinomas. Oncogene 2006;25:5018-26.
8. Kraunz KS, Hsiung D, McClean MD, et al. Dietary folate is associated with p16(INK4A) methylation in head and neck squamous cell carcinoma. Int J Cancer 2006;119:1761-6.
9. Smith LT, Lin M, Brena RM, et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-24 in lung and head and neck cancer. Proc Natl Acad Sci U S A 2006;103:982-7.
10. Crowe DL, Hacia JG, Hsieh CL, et al. Molecular pathology of head and neck cancer. Histol Histopathol 2002;17:909-14.
11. Marsit CJ, Liu M, Nelson HH, et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004;23:1000-4.
12. Esteves LI, Javaroni AC, Nishimoto IN, et al. DNA methylation in the CTCF-binding site I and the expression pattern of the H19 gene: does positive expression predict poor prognosis in early stage head and neck carcinomas? Mol Carcinog 2005;44:102-10.
13. Roepman P, Wessels LF, Kettelarij N, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005;37:182-6.
14. Porse BT, Bryder D, Theilgaard-Monch K, et al. Loss of C/EBP α cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage. J Exp Med 2005;202:85-96.
15. Halmos B, Huettner CS, Kocher O, et al. Down-regulation and antiproliferative role of C/EBPα in lung cancer. Cancer Res 2002;62:528-34.
16. Tada Y, Brena RM, Hackanson B, et al. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein a activity in lung cancer. J Natl Cancer Inst 2006;98:396-406.
17. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 2005;102:15785-90.
18. Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-γ activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004;53:2748-56.
19. Heckman CA, Wheeler MA, Boxer LM. Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene 2003;22:7891-9.
20. Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624-33.
21. Timchenko N, Wilson DR, Taylor LR, et al. Autoregulation of the human C/EBP α gene by stimulation of upstream stimulatory factor binding. Mol Cell Biol 1995; 15:1192-202.
22. Efimova T, Eckert RL. Regulation of human involucrin promoter activity by novel protein kinase C isoforms. J Biol Chem 2000;275:1601-7.
23. Balasubramanian S, Agarwal C, Efimova T, et al. Thapsigargin suppresses phorbol ester-dependent human involucrin promoter activity by suppressing CCAAT-enhancer-binding protein α (C/EBPα) DNA binding. Biochem J 2000;350 Pt 3:791-6.
24. Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development: part II. The C/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. Pharmacol Rev 2004;56:291-330.
25. Roepman P, de Jager A, Groot Koerkamp MJ, et al. Maintenance of head and neck tumor gene expression profiles upon lymph node metastasis. Cancer Res 2006; 66:11110-4.
26. Bockmuhl U, Wolf G, Schmidt S, et al. Genomic alterations associated with malignancy in head and neck cancer. Head Neck 1998;20:145-51.
27. Hogg RP, Honorio S, Martinez A, et al. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer 2002;38: 1585-92.
28. McKie AB, Douglas DA, Olijslagers S, et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 2005;24:2166-74.
29. Chopin V, Leprince D. [Chromosome arm 17p13.3: could HICI be the one?]. Med Sci (Paris) 2006;22:54-61.
30. Woo IS, Park MJ, Choi SW, et al. Loss of estrogen receptor-α expression is associated with hypermethylation near its ATG start codon in gastric cancer cell lines. Oncol Rep 2004;11:617-22.
31. Nicoll G, Crichton DN, McDowell HE, et al. Expression of the hypermethylated in cancer gene (HIC-1) is associated with good outcome in human breast cancer. Br J Cancer 2001;85:1878-82.
32. Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001;27:427-30.
33. Sabbir MG, Roy A, Mandal S, et al. Deletion mapping of chromosome 13q in head and neck squamous cell carcinoma in Indian patients: correlation with prognosis of the tumour. Int J Exp Pathol 2006;87:151-61.
34. Gasparotto D, Vukosavljevic T, Piccinin S, et al. Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. Int J Cancer 1999;84:432-6.
35. Lee DJ, Koch WM, Yoo G, et al. Impact of chromosome 14q loss on survival in primary head and neck squamous cell carcinoma. Clin Cancer Res 1997;3:501-5.
36. Yang MH, Chiang WC, Chou TY, et al. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clin Cancer Res 2006;12:507-15.
37. Silva SD, Agostini M, Nishimoto IN, et al. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. Oral Oncol 2004;40:688-96.
38. Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004;111:213-7.
39. Masuda M, Suzui M, Lim JT, et al. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 2003;9:3486-91.
40. Xu YP, Zhao XQ, Sommer K, et al. Correlation of matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis. J Zhejiang Univ Sci 2003;4: 491-501.
41. Namazie A, Alavi S, Olopade OI, et al. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002;112:472-81.
42. Chin D, Boyle GM, Williams RM, et al. Alpha B-crystallin, a new independent marker for poor prognosis in head and neck cancer. Laryngoscope 2005;115:1239-42.
43. Dhawan D, Hamdy FC, Rehman I, et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathology 2006;209:336-43.
44. Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006;66:1208-17.
45. Tornayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.